However, Sun et al. [29] further reported that compared with platinum chemotherapy, DC-CIK therapy could significantly increase the proportions of CD3+ T cells, CD3+ CD4+ T cells, and the ratio of CD4+/CD8+ T cells in NSCLC. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.